ALBO 外匯新聞
Albireo Pharma Posts Positive Topline Results From Phase 3 Study Of Bylvay In Alagille Syndrome
Albireo Pharma, Inc. (ALBO) announced Tuesday positive topline results from the Phase 3 ASSERT study evaluating the safety and efficacy of Bylvay in Alagille syndrome (ALGS) patients from birth to early adulthood.
RTTNews
|
830天前
